

Brno Oncology Days
Nursing Conference

Conference Programme

3–5 September 2025
Brno, Exhibition Centre, Hall E



www.onkologickedny.cz/en



NETWORKING BRINGS PROFESSIONALS TOGETHER

Join us in Brno and network with your colleagues, interact with key opinion leaders, ask questions and debate on burning topics in the field of medical oncology in a uniquely meaningful way.

SEE YOU AT BOD 2026
9–11 SEPTEMBER 2026

CONTENT

Introduction2

Conference plan 4

CONFERENCE PROGRAMME 6

THURSDAY / R. WERNER HALL8

International Brno Oncology Days8

 Clinical Research8

 Breaking News 20258

 Esophagogastric and Pancreatic Cancer.....9

 Colorectal Cancer9

FRIDAY / R. WERNER HALL.....10

International Brno Oncology Days10

 Case Reports10

 Precision Medicine10

 Endocrine and Neuroendocrine Tumours.....10

INVITED SPEAKERS

Jakub Kucharz 12

Sara Lonardi..... 13

Florian Lordick..... 14

Maximilian Mair..... 15

Giuseppe Minniti 16

Ayşegül İlhan-Mutlu 17

Eric Van Cutsem..... 18

Kjetil Taskén 19

Christos Toumpanakis 20



INTRODUCTION

Dear colleagues and friends,

On behalf of the Masaryk Memorial Cancer Institute and the Organising and Programme Committees, it is our great pleasure to welcome you to the **49th Brno Oncology Days** and the **39th Nursing Conference**. This long-standing professional event with an international dimension remains the largest platform in the Czech Republic for interdisciplinary dialogue among all professions engaged in the field of oncology.

In 2024, we welcomed more than 2,500 participants, including 22 invited international speakers. Over the course of the conference, more than 350 contributions were presented, among them 290 oral presentations delivered within 43 educational sessions and 10 free communication sessions.

As in previous years, the Wednesday programme opens with the multidisciplinary **Glio Meeting**, dedicated to brain tumours. The programme further includes thematic seminars on gynaecologic oncology, data and informatics in oncology, and palliative care. A seminar for **general practitioners and non-oncologists** will focus not only on collaboration between primary care physicians and palliative care teams, but also on specific aspects of oncology patient care from the perspectives of internal medicine, psychiatry, pulmonology, dermatology, and nutrition. You can also look forward to sessions covering topics such as secondary and tertiary prevention, tumour biology, and oncological surgery.

Thursday's scientific programme will feature traditional educational seminars on breast cancer, pneumooncology, radiotherapy and immunotherapy of lung cancers, and uro-oncology. Attention will also be given to cancer prevention and early detection, as well as interventional radiology.

Running in parallel throughout the day will be the associated conference **Laboratory Diagnostics in Oncology**.

The Friday programme will again include well-established sessions on nutritional care in oncology and oncology pharmacy. A new feature this year is a series of workshops for physicians.

Following the enthusiastic reception of last year's **Psycho-Oncology Conference**, this year's edition continues under the new subtitle "Illness as Trauma – Trauma in Oncology".

The **International Brno Oncology Days (IBOD)** enter their fifth year in 2025 and will take place on 4–5 September. The core mission remains to deepen Central European cooperation between clinicians and researchers. We are delighted to welcome distinguished experts this year from **Leipzig, Vienna, Leuven, Oslo, Padua, London, Warsaw, and Rome**, among others. The IBOD programme will offer not only the latest updates, but also educational sessions devoted to gastrointestinal cancers, precision medicine, and endocrine and neuroendocrine tumours. We place special emphasis on fostering intergenerational exchange among professionals, which we see as vital to the future of our field.

A completely new element of this year's programme is the **ONCO Cinema** – a space where recordings of examinations, surgeries, and procedures will be screened, accompanied by annotated commentary and followed by expert discussions.

The **Nursing Conference** will this year present, among other topics, updates in cancer prevention and screening programmes, as well as developments in the competencies and education of non-medical staff. As always, popular hands-on workshops will be included, this year focusing on nutrition, prevention, and the role of the case manager in the patient's care pathway.

We are honoured that the conference is once again held under the auspices of **ESMO**, the **Czech Oncological Society**, and other professional organisations.

We greatly value that Brno Oncology Days are regarded not only as a high-level professional event, but also as a social gathering of colleagues and friends. We trust that this year's edition will meet these expectations. In addition to Wednesday's ceremonial opening, you can look forward to Thursday's social evening at the OREA Congress Hotel, which will include the presentation of awards to distinguished figures in the field.

We look forward to spending these days together in Brno and to inspiring professional and personal encounters.



Assoc. Prof. Radka Lordick Obermannová, MD, PhD
Chair of the BOD Programme Committee




Tereza Malá, MBA
Chair of the Nursing Conference
Programme Committee




Prof. Marek Svoboda, MD, PhD
General Director of the Masaryk
Memorial Cancer Institute

BRNO EXHIBITION CENTRE




BRNO, KŘÍŽKOVSKÉHO, PAVILON E →






2ND
FLOOR



1ST
FLOOR



GROUND
FLOOR

CONFERENCE PROGRAMME

Thursday 4 September 2025	International Brno Oncology Days
	R. Werner Hall
9:20–10:50	Clinical Research
10:50–11:00	BREAK
11:00–12:30	Breaking News 2025 *
12:30–13:30	LUNCH
14:40–16:10	Esophagogastric and Pancreatic Cancer *
16:10–16:30	COFFEE BREAK
16:30–18:00	Colorectal Cancer *
18:30–24:00	GALA DINNER

*Simultaneous interpretation is provided in this session.

Friday 5 September 2025	International Brno Oncology Days
	R. Werner Hall
8:00–9:30	Case Reports
9:30–9:50	COFFEE BREAK
9:50–11:20	Precision Medicine
11:20–11:30	BREAK
11:30–13:00	Endocrine and Neuroendocrine Tumours
13:00–13:30	LUNCH

09:20–10:50 IBOD CLINICAL RESEARCH

Chairs: O. Slabý, L. Moráňová (Brno)

- 09:20 87. **FUNCTIONAL ANALYSIS AND VALIDATION OF CANDIDATE TARGETS, RELEVANT IN ADAPTIVE OESOPHAGEAL ADENOCARCINOMA RESPONSE – FROM ACQUIRED RESISTANCE TO ACQUIRED VULNERABILITY AND TREATMENT OPTIMISATION**

G. Costella (Leipzig)

- 09:30 88. **FUNCTIONAL CHARACTERIZATION OF NOVEL THERAPEUTIC APPROACHES IN ESOPHAGEAL ADENOCARCINOMA**

Z. Trybala, P. Müller, R. Lordick Obermannová (Brno)

- 09:40 89. **HEART RATE VARIABILITY – NEURO-TUMOROUS INTERACTIONS IN PANCREATIC CANCER**

B. Špánik, B. Mravec, M. Mego (Bratislava)

- 09:50 90. **BIOMARKERS OF UROTHELIAL CARCINOMA ASSOCIATED WITH RESISTANCE TO CISPLATIN**

M. Paulovičová, A. Holíčková, E. Órásová, J. Obertová, M. Chovanec, J. Roška, M. Chovanec, P. Palacka (Bratislava)

- 10:00 91. **ACUTE BLEOMYCIN TOXICITY IN GERM CANCER PATIENTS**

P. Oláh, K. Rejleková (Bratislava)

- 10:10 92. **CUTTING-EDGE ELECTROCHEMICAL BIOPLATFORMS FOR FUSION GENE IDENTIFICATION**

N. Izadi, A. Borisova, M. Bartošik (Brno)

- 10:20 93. **PREHABILITATION IN GYNECOLOGIC ONCOLOGY – THE PHOCUS STUDY**

M. Borčinová, D. Cibula, M. Kníže (Prague)

- 10:30 94. **CERVANTES – AN INTERNATIONAL RANDOMISED TRIAL OF RADICAL SURGERY FOLLOWED BY ADJUVANT THERAPY VERSUS NO FURTHER TREATMENT IN PATIENTS WITH EARLY-STAGE, INTERMEDIATE-RISK CERVICAL CANCER (CEEgOG-CX-05; ENGOT-CX16)**

P. Jestřábová, M. Borčinová, R. Kocián, D. Feltl, S.. Argalácsová, P. Dvořák, D. Fischerová, P. Dundr, J. Jarkovský, J. Sláma, D. Cibula (Prague, Brno)

10:40 Discussion

10:50 Break

11:00–12:30 IBOD BREAKING NEWS 2025*

Chairs: R. Lordick Obermannová, Š. Pörsök (Brno, Bratislava)

- 11:00 95. **BREAKING NEWS IN GYNECOLOGICAL TUMOURS**

D. Cibula (Prague)

- 11:15 96. **BREAKING NEWS IN GENITOURINARY TUMOURS**

J. Kucharz (Warsaw)

- 11:30 97. **MSI-H AS A TARGET AND NEW MOLECULES ON HORIZON IN GASTROINTESTINAL TUMOURS**

F. Lordick (Leipzig)

- 11:45 98. **INTEGRATION OF NOVEL BIOMARKERS IN THE TREATMENT OF LUNG CANCER**

M. Knetki-Wróblewska (Warsaw)

- 12:00 99. **EANO-ESTRO GUIDELINE: CURRENT RECOMMENDATIONS AND FUTURE PROSPECTIVES**

G. Minniti (Rome)

12:15 Discussion

12:30 Lunch

14:30 Break

14:40–16:10 IBOD ESOPHAGOGASTRIC AND PANCREATIC CANCER*

Moderator: R. Lordick Obermannová (Brno)

14:40 Opening

14:45 103. EMERGING NEWS IN UPPER GI TUMOURS TREATMENT

A. Ilhan-Mutlu (Vienna)

15:00 104. MINIMAL INVASIVE SURGERY AND THE IMPACT OF A COMPREHENSIVE PREOPERATIVE PROGRAM ON OESOPHAGEAL CANCER PATIENT OUTCOMES

S. Schoppmann (Vienna)

15:15 PANEL DISCUSSION

R. Pohnán, B. Bencsiková, V. Jedlička, F. Lordick, A. Ilhan-Mutlu, S. Schoppmann (Prague, Brno, Leipzig, Vienna)

Moderator: R. Němeček (Brno)

15:30 105. EMPOWERING HOPE: A TREATMENT ALGORITHM FOR LOCALIZED PANCREATIC CANCER AND THE POSSIBILITY OF INDIVIDUALIZED CARE

G. Prager (Vienna)

15:45 PANEL DISCUSSION

B. Mohelníková Duchoňová, G. Prager, E. Van Cutsem, S. Lonardi, L. Sirotek, M. Vočka (Brno, Olomouc, Vienna, Leuven, Padua, Prague)

16:00 Closing

16:10 Coffee break

16:30–18:00 IBOD COLORECTAL CANCER*

Moderator: I. Kiss (Brno)

Chairs: E. Van Cutsem, S. Lonardi, J. Tomášek, R. Soumarová, J. Křístek, M. Vočka (Leuven, Padua, Brno, Prague)

16:30 Opening

16:35 106. PERSONALIZED APPROACH TO THE TREATMENT OF LOCALIZED COLORECTAL CANCER

E. Van Cutsem (Leuven)

16:55 107. EMERGING MOLECULES AND STANDARD OF CARE FOR METASTATIC COLORECTAL CANCER

S. Lonardi (Padua)

17:15 108. PANEL DISCUSSION: ADVANCES IN COLORECTAL CANCER TREATMENT

* Simultaneous interpretation is provided in this session.



08:00–09:30 IBOD CASE REPORTS

Chairs: A. Ilhan-Mutlu, F. Lordick, J. Kucharz
(Vienna, Leipzig, Warsaw)

- 08:00 208. **IS POOR PERFORMANCE STATUS AND MULTIORGAN FAILURE ALWAYS A CONTRAINDICATION TO CHEMOTHERAPY? A CASE REPORT OF A PATIENT WITH METASTATIC GCT TREATED IN THE ICU**
M. Piętak (Warsaw)

- 08:15 209. **TARGETED THERAPEUTIC APPROACHES IN AN ELDERLY PATIENT WITH ADVANCED GASTRIC ADENOCARCINOMA**
E. Bergen (Vienna)

- 08:30 210. **NEOADJUVANT TRASTUZUMAB DERUXTECAN IN RESECTABLE, HER2-POSITIVE GEJ ADENOCARCINOMA: A CASE REPORT FROM THE NEOART TRIAL**
A. Krause (Leipzig)

- 08:45 211. **CHALLENGES OF NONOPERATIVE MANAGEMENT IN MSI-H LOCALLY ADVANCED RECTAL CANCER: A CASE REPORT**
M. Kysela, R. Lordick Obermannová, Z. Chovanec, M. Knoz (Brno)

- 09:00 212. **FGFR AS A THERAPEUTIC TARGET IN THE TREATMENT OF PANCREATIC CANCER**
Z. Mináriková (Bratislava)
- 09:15 Discussion

09:50–11:20 IBOD PRECISION MEDICINE

Chairs: P. Grell, S. Lonardi, M. Mair, K. Taskén
(Brno, Padua, Vienna, Oslo)

- 09:50 213. **PRECISION ONCOLOGY IN GI TUMOURS**
S. Lonardi (Padua)

- 10:05 214. **PRECISION MEDICINE IN THE TREATMENT OF BRAIN TUMOURS**
M. Mair (Vienna)

- 10:20 215. **THE ROLE OF LIQUID BIOPSY FOR PRECISION ONCOLOGY IN COLORECTAL CANCER**
U. Hacker (Leipzig)

- 10:35 216. **BUILDING BRIDGES IN PRECISION ONCOLOGY: GENESIS – THE CZECH MOLECULAR TUMOUR BOARD NETWORK**
P. Grell (Brno)

- 10:50 217. **ADVANCING PRECISION CANCER MEDICINE BY BUILDING NATIONAL INITIATIVES AND VIA EUROPEAN COLLABORATION**
K. Taskén (Oslo)

- 11:05 Discussion

- 11:20 Break

11:30–13:00 IBOD ENDOCRINE AND NEUROENDOCRINE TUMOURS

Chairs: Š. Tuček, B. Bencsiková, L. Křížová
(Brno, Prague)

- 11:30 218. **BEST OF ENETS**
B. Bencsiková (Brno)

- 11:45 219. **INDICATION AND SIDE EFFECTS OF PRRT**
W. de Herder (Rotterdam)

- 12:05 220. **MANAGEMENT OF CARCINOID SYNDROME – IMPLEMENTATION OF GUIDELINES INTO CLINICAL PRACTICE**
C. Toumpanakis (London)

- 12:30 221. **MANAGEMENT OF ADRENOCORTICAL CANCER**
L. Křížová (Prague)
- 12:45 Discussion

- 13:00 Lunch





Prof. Jakub Kucharz, MD

Maria Skłodowska-Curie National Research Institute of Oncology, Poland

BREAKING NEWS IN GENITOURINARY TUMOURS

Thursday 4. 9. 2025, 11:15 a.m., R. Werner Hall

Dr. Kucharz is associate professor of medical oncology at Maria Skłodowska-Curie National Research Institute of Oncology. He graduated Jagiellonian University Medical College. Dr. Kucharz is board-certified medical oncologist focused on genitourinary oncology and supportive care.

He is General Secretary of the Executive Board of Polish Society of Clinical Oncology and secretary of the Supportive Care Section of Polish Society of Clinical Oncology. He is also the member of European Society for Clinical Oncology.

Dr. Kucharz research interests are focused on prognostic and predictive factors for targeted therapies and immunotherapy, adverse events management and treatment of critically-ill germ cell tumor patients.

He published over 60 articles in peer-reviewed journals. He is also an co-author of clinical practice guidelines (GU tumors) of Polish Society of Clinical Oncology. Dr. Kucharz serves as peer reviewer for several medical journals.

Selected recent papers:

1. Kucharz J, Poprach A, Sikora-Kupis B, Darewicz M, Domański P, Bezděková M, et al. Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project. *Clin Genitourin Cancer*. 2025; 23(4): 102382.
2. Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L et al. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? *Eur Urol Oncol* 2024; 7(1): 102–111.

3. Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, Myint ZW, Kucharz J, Molina-Cerrillo J, Santini D et al. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. *Cancer Immunol Immunother* 2024; 73(8): 142.

4. Kuncman Ł, Orzechowska M, Milecki T, Kucharz J, Fijuth J. High FLT3 expression increases immune-cell infiltration in the tumor microenvironment and correlates with prolonged disease-free survival in patients with non-small cell lung cancer. *Mol Oncol* 2024; 18(5): 1316–1326.

5. Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. *Cancer Immunol Immunother* 2023; 72(6): 1365–1379.

6. Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R... Kucharz J et al. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. *Cancer Immunol Immunother* 2023; 72(11): 3665–3682.

As part of the Brno Oncology Days, Dr. Kucharz will deliver an invited lecture on the topic “Breaking News in Genitourinary Tumours”.



Prof. Sara Lonardi, MD

Oncology 1 Unit, Veneto Institute of Oncology – IRCCS, University of Padua, Italy

EMERGING MOLECULES AND STANDARD OF CARE FOR METASTATIC COLORECTAL CANCER

Thursday 4. 9. 2025, 4:55 p.m., R. Werner Hall

PRECISION ONCOLOGY IN GI TUMOURS

Friday 5. 9. 2025, 9:50 a.m., R. Werner Hall

Sara Lonardi, MD, is the Head of the Oncology 1 Unit of Veneto Institute of Oncology (IOV) – IRCCS.

She obtained her Medical Degree in 2000 and completed her specialization in Oncology in 2004, both at the University of Padua. She has been actively interested in the care of gastrointestinal cancer patients since 1998. In 2013 she was appointed chief of the GI Cancer Unit of IOV-IRCCS, being involved in several international and national clinical trials as Principal Investigator. In addition to her work in GI oncology, she served as the Chief of Phase I Clinical Trial Unit at IOV-IRCCS and pro tempore Chief of the Oncology 3 Unit at IOV-IRCCS, reflecting her broad expertise and leadership across multiple oncology programs.

She has published more than 200 scientific articles in peer-reviewed journals dealing with gastrointestinal cancers clinical and translational research.

She is an active member of several professional organizations, including the Associazione Italiana di Oncologia Medica (AIOM), European Society of Medical Oncology (ESMO) and American Society of Medical Oncology (ASCO). Additionally, she contributes to the scientific community as a member of the Steering Committee of the ACCENT DataBase, a key resource in colorectal cancer research.

Selected recent publications:

1. Pietrantonio F, Durinikova E, Amatu A, Tosi F, Cassingena A, Rizzetto F, Buzo K, Arcella P, Aquilano MC, Bonoldi E, Marsoni S, Siena S, Bardelli A, Sartore Bianchi A, Lonardi S. KRASG12D Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration. *JCO Precis Oncol.* 2024; 8: e2400329.
2. Bergamo F, Dalla Santa S, Loupakis F, Cerma K, Tosi A, De Grandis C, Dalla Pietà A, Gringeri E, Angerilli V, Ramondo G... Lonardi S. Complete pathologic response with first-line immunotherapy combination in a young adult with mismatch repair – deficient metastatic colorectal cancer: immunological and molecular profiling. *Front Oncol.* 2022; 12: 964219.
3. Sartore Bianchi A, Pietrantonio F, Lonardi S et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. *Nat Med.* 2022; 28(5): 1124–1131.
4. Elez E, Ros J, Fernández J, Villacampa G, Moreno Cárdenas AB ... Lonardi S et al. RNF43 mutations predict response to anti BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer. *Nat Med.* 2022; 28(5): 1132–1141.

As part of the Brno Oncology Days, Prof. Sara Lonardi will present invited lectures on „Emerging Molecules and Standard of Care for Metastatic Colorectal Cancer” and „Precision Oncology in GI Tumours”.



Prof. Florian Lordick, MD, PhD

University Cancer Center Leipzig, Leipzig University Medical Center, Leipzig, Germany

MSI-H AS A TARGET AND NEW MOLECULES ON HORIZON IN GASTROINTESTINAL TUMOURS

Thursday 4. 9. 2025, 11:30 a.m., R. Werner Hall

Florian Lordick is a Full Professor of Medicine at the University of Leipzig, Germany. He was appointed as director of the University Cancer Center Leipzig in 2012, which, in collaboration with the University of Jena Medical Center, recently was awarded as one of 15 German Oncology Centers of Excellence and receives funding from the German Cancer Aid. He also is head of the Department of Medicine (oncology, gastroenterology, hepatology, and pulmonology) at the University of Leipzig Medical Center.

Dr. Lordick's scientific focus is on clinical and translational research in immuno-oncology and targeted treatment of cancer, with a specific focus on gastrointestinal tract tumours. He has a great interest in multimodality treatment of GI cancers, in personalized medicine and in survivorship topics. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commission.

Dr. Lordick has authored and co-authored more than 400 peer-reviewed and PubMed-listed articles. Dr. Lordick served as Director of Education at the European Society for Medical Oncology (ESMO) from 2019 to 2022, as president of the International Gastric Cancer Association (IGCA) and he is a former member of the executive board of the German Cancer Society and former chair of the EORTC Gastrointestinal Tract Cancer Working groups.

He holds reviewer and advisory roles at various research funding organizations and European comprehensive cancer centers. He also is the newly appointed Editor-in-Chief of ESMO Gastrointestinal Oncology, official scientific journal of the European Society for Medical Oncology.

Selected recent papers:

1. Hoepfner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, Izicki JR, Gockel I, Gerdes B ... Lordick F. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. *N Engl J Med.* 2025; 392(4): 323–335.
2. Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Naftoux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis a, Piessen G, Bruns CJ, Lordick F et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). *Eur J Cancer* 2024; 204: 114062.
3. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *Lancet* 2023; 401(10389): 1655–1668.
4. Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Türeci Ö. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. *J Cancer Res Clin Oncol* 2023; 149(9): 5937–5950.

As part of the Brno Oncology Days, Prof. Lordick will deliver an invited lectures on the topic “MSI-H as a Target and New Molecules on Horizon in Gastrointestinal Tumours”.



Maximilian Mair, MD, PhD

Division of Oncology, Medical University of Vienna, Austria

PRECISION MEDICINE IN THE TREATMENT OF BRAIN TUMOURS

Friday 5. 9. 2025, 10:05 a.m., R. Werner Hall

Dr. Maximilian Mair is a physician-scientist based at the Division of Oncology, Medical University of Vienna. His work centers on clinical and translational neuro-oncology, with a focus on primary brain tumors in adults, particularly the development of personalized systemic treatment approaches and the discovery of novel biomarkers. He completed his medical degree in 2018 and his doctoral studies (PhD) in 2023 at the Medical University of Vienna, where his dissertation focused on the clinical and immunological characterization of lower-grade gliomas.


Dr. Mair pursued a postdoctoral research fellowship at Ludwig Maximilian University Munich, where he explored diagnostic and therapeutic applications of nuclear medicine in neuro-oncology, particularly theranostic strategies and molecular imaging. His return to Vienna marked a continued dedication to bridging laboratory findings with clinical applications in neuro-oncology.

Dr. Mair has authored numerous peer-reviewed publications and has contributed to international clinical guidelines and expert consensus statements. He is actively involved in the European Association of Neuro-Oncology and the European Organisation for Research and Treatment of Cancer – Brain Tumour Group, where actively contributes as Young Neuro-Oncologist (YNO) member of the Steering Committee. His research has been supported by several national and international competitive grants, and he has received multiple awards recognizing his scientific contributions. In addition to his academic and clinical responsibilities, he also mentors junior researchers entering the field of neuro-oncology.

Selected recent publications:

1. Mair MJ, Leibetseder A, Heller G, Tomasich E, Müller L, Busse I, Wöhrer A, Kiesel B, Widhalm G, Eckert F, Weis S, Pichler J, Preusser M, Berghoff AS. Clinical characteristics, molecular reclassification trajectories and DNA methylation patterns of long- and short-term survivors of WHO grade II and III glioma. *J Neurol.* 2025; 272(3): 210.
2. Mair MJ, Bartsch R, Le Rhun E, Berghoff AS, Brastianos PK, Cortes J, Gan HK, Lin NU, Lassman AB, Wen PY, Weller M, van den Bent M, Preusser M. Understanding the activity of antibody drug conjugates in primary and secondary brain tumors. *Nat Rev Clin Oncol* 2023; 20(6): 372–389.
3. Mair MJ, Leibetseder A, Heller G, Puhr R, Tomasich E et al. Early postoperative treatment versus initial observation in CNS WHO grade 2 and 3 oligodendroglioma: clinical outcomes and DNA methylation patterns. *Clin Cancer Res* 2022; 28(20): 4565–4573.
4. Sahm F, Bertero L, Brandner S, Capper D, Goldbrunner R, Jenkinson MD, Kalamirides K, Lamszus K, Albert NL, Mair MJ et al. EANO guideline on molecular testing of meningiomas for targeted therapy selection. *Neuro Oncol* 2025; 27(4): 869–883.
5. Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Ciccone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. *Lancet Oncol* 2024; 25(1): e29–e41.

As part of the Brno Oncology Days, Dr. Maximilian Mair will present an invited lecture on „Precision Medicine in the Treatment of Brain Tumours“.



Prof. Giuseppe Minniti, MD, PhD

Radiation Oncology Unit, Sapienza University of Rome, Italy

EANO-ESTRO GUIDELINE: CURRENT RECOMMENDATIONS AND FUTURE PROSPECTIVES

Thursday 4. 9. 2025, 12:00 noon, R. Werner Hall

Giuseppe Minniti, MD, PhD, is Professor and Chair of Radiation Oncology at the University Hospital Policlinico Umberto I and Sapienza University of Rome. He is a recognized expert in the treatment of primary and secondary brain tumors, with over two decades of clinical and research experience in neuro-oncology and advanced radiation techniques.

Prof. Minniti received his medical degree and PhD from Sapienza University of Rome, and completed clinical and research fellowships at leading international institutions, including The Royal Marsden Hospital (London), Massachusetts General Hospital (Boston), and the Paul Scherrer Institute (Switzerland). He has held academic appointments at the Universities of Siena, Pittsburgh, and Sapienza, and is currently involved in teaching medical and radiation oncology across multiple programs.

His research focuses on image-guided radiotherapy, radiosurgery, treatment-related neurotoxicity, and the integration of radiotherapy with systemic therapies. He is the coordinator of several clinical research projects in gliomas and brain metastases and has authored numerous peer-reviewed publications in these areas.

Prof. Minniti is an active member of several key European and international organizations, including EORTC, ESTRO, EANO, and ASTRO. He currently serves on multiple scientific and steering committees and is a senior associate editor or board member for journals such as Neuro-Oncology, IJROBP, Radiotherapy and Oncology, and Neuro-Oncology Advances.

Selected recent publications:

1. Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM... Minniti G. International Consortium on Meningiomas (ICOM) et al. Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients. *Neuro Oncol.* 26(10): 1742–1780.
2. Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Ciccone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. *Lancet Oncol.* 2024; 25(1): e29–e41.
3. Minniti G, Tini P, Giraffa M, Capone L, Raza G, Russo I, Cinelli E, Gentile P, Bozzao A, Paolini S, Esposito V. Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. *Radiother Oncol.* 2023; 181: 109435.
4. Weller M, Le Rhun E, Van den Bent M, Chang SM, Cloughesy TF, Goldbrunner R, Hong YK, Jalali R, Jenkinson MD, Minniti G et al. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. *Neuro Oncol.* 2023; 25(7):1200–1224.

As part of the Brno Oncology Days, Prof. Giuseppe Minniti will present an invited lecture on „EANO-ESTRO Guideline: Current Recommendations and Future Prospectives“.



Assoc. Prof. Ayşegül İlhan-Mutlu, MD, PhD, PD

Division of Oncology, Medical University of Vienna, Austria

EMERGING NEWS IN UPPER GI TUMOURS TREATMENT

Thursday 4. 9. 2025, 2:45 p.m., R. Werner Hall

Assoc. Prof. Ayşegül İlhan-Mutlu is a medical oncologist at the Division of Oncology, Department of Medicine I, Medical University of Vienna, and Vienna General Hospital. Her clinical and research focus spans primary and metastatic central nervous system tumors, as well as gastroesophageal malignancies.

She obtained her MD in 2007 from MedUni Vienna and completed her PhD in internal medicine in 2015, focusing on the “Characterization of C20orf3 Gene.” In 2017, she achieved habilitation with a thesis on circulating and tissue based cancer biomarkers. She completed board certification in Internal Medicine (2018) and her residency in Medical Oncology (2021), both at MedUni Vienna.

Her international experience includes a 2013–14 research visit to the German Cancer Research Center (DKFZ) in Heidelberg, supported by an ESMO Translational Research Fellowship, where she investigated prevention of brain metastases in non small cell lung cancer model. Dr. İlhan-Mutlu is currently director of the Gastroesophageal Tumors Unit and plays a leading clinical and research role within the Central Nervous System Tumors Unit at the Comprehensive Cancer Center Vienna. She has authored or co authored more than 100 scientific publications, with over 1400 citations.

She is an active member of major professional societies including ESMO, ASCO, EORTC (Brain Tumour Group and GI Tumors Group), IGCA and SANO (Austrian Society for Neuro Oncology). Her awards include the ESMO Translational Research Fellowship (2013) for work on anti angiogenic therapy in brain metastasis prevention, and the ESMO Open Best Review of the Year Prize (2020).

Selected recent publications:

1. Korpan M, Pühr HC, Prager GW, Preusser M, İlhan-Mutlu A. Current landscape of molecular biomarkers in gastroesophageal tumors and potential strategies for co expression patterns. *Cancers (Basel)*. 2025; 17(3): 340.
2. İlhan-Mutlu A. Highlights on gastroesophageal tumors: the comeback of FLOT. *Memo (Magazine European Med Oncol)*. 2025; 18: 34–37.
3. İlhan-Mutlu A. Emerging molecular drugs for the treatment of gastroesophageal tumors. *Magazine Eur Med Oncol*. 2023; 16: 198–199.
4. Pühr HC, Reiter TJ, Preusser M, Prager GW, İlhan-Mutlu A. Recent advances in the systemic treatment of localized gastroesophageal cancer. *Cancers (Basel)*. 2023; 15(6): 1900.
5. Pühr HC, İlhan-Mutlu A.: Molecular profiling in gastroesophageal cancer – clinical routine and future perspective. *Magazine Eur Med Oncol* 2020; 13: 440–444.

As part of the Brno Oncology Days, Assoc. Prof. İlhan-Mutlu will present an invited lecture on “Emerging News in Upper GI Tumours Treatment”.



Prof. Eric Van Cutsem, MD, PhD

University of Leuven, University Hospitals Gasthuisberg, Belgium

PERSONALIZED APPROACH TO THE TREATMENT OF LOCALIZED COLORECTAL CANCER

Thursday 4. 9. 2025, 4:35 p.m., R. Werner Hall

Eric Van Cutsem is full professor at the University of Leuven and the University Hospitals Gasthuisberg and since October 2023 Professor Emeritus with tasks at the University of Leuven, amongst which Board member of the Faculty of Medicine of University of Leuven. He is a member of the Belgian Royal Academy of Medicine and president of the Belgian Foundation against Cancer.

In 2018 he became doctor honoris causa of the Medical University of Warsaw and received several national and international awards, amongst which were in 2019 the ESMO Award and the European Awards in Medicine for Cancer Research.

Prof. Van Cutsem has authored over 750 PubMed-indexed papers and more than 1,650 publications according to Web of Science, with over 125,000 citations and an H-index of 154. He ranks among the global top 1% of most cited researchers in Clinical Medicine, and is one of the top three most cited medical scientists in Belgium.

His research interests are various aspects of Gastrointestinal and Digestive cancers (colorectal, gastric, pancreas, bile duct, esophageal cancer and neuroendocrine tumors). He serves on many industry advisory boards for new anti-cancer drugs and treatment modalities and Independent Data Monitoring Committee of clinical trials.

He is known as world wide clinical expert in Gastrointestinal Oncology and consults for patients across the globe and featured in Belgium in the media program: Topdokters.

He co-founded and is chair of ESMO/World Congress on Gastrointestinal Cancer in Barcelona, Spain and continues to chair ESMO GI.

He has served in leadership or advisory roles with ESMO, UEG, ASCO, ENETS, EORTC, ECO, ESDO (as past president), ESO, and patient advocacy groups including EuropaColon and Digestive Cancers Europe. In 2025, he will join the Scientific Council of IARC/WHO.

He was chairman of the governmental colon cancer prevention task force in Flanders, was/is in Belgian active as president and treasurer

of Belgian Group Digestive Oncology and as president/vice-president of Familial Polyposis Association.

He has advised major cancer centers in France, Germany, and Italy, and currently is member of the board of directors of the regional hospital of Halle and member of the board of CUROZ. He contributed to the legal recognition of Digestive Oncology in Belgium and served on the governmental accreditation commission.

Selected recent publications:

1. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al.; MATTERHORN Investigators. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. *N Engl J Med.* 2025; 393(3): 217–230.
2. Shitara K, Van Cutsem E, Gümüş M, DESTINY-Gastric04 Trial Investigators. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. *N Engl J Med.* 2025; 393(4): 336–348.
3. Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, et al.; BREAKWATER Trial Investigators. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. *N Engl J Med.* 2025; 392(24): 2425–2437.

As part of the Brno Oncology Days, Prof. Eric Van Cutsem will present an invited lecture on „Personalized Approach to the Treatment of Localized Colorectal Cancer“.



Prof. Kjetil Taskén, MD, PhD

Institute of Cancer Research, Oslo University Hospital, University of Oslo, Norway

ADVANCING PRECISION CANCER MEDICINE BY BUILDING NATIONAL INITIATIVES AND VIA EUROPEAN COLLABORATION

Friday 5. 9. 2025, 10:50 a.m., R. Werner Hall

Kjetil Taskén was appointed Professor of Medicine at University of Oslo (UiO) in 2001 and has since 2018 served as Head of the Institute of Cancer Research, Oslo University Hospital where he is also Group Leader for the Cell Signaling and Immune Regulation Group in the Department of Cancer Immunology. He was the Director of the Biotechnology Centre of Oslo, UiO, from 2003 to 2016, and the founding Director of Centre for Molecular Medicine Norway, Nordic EMBL Partnership, UiO, where he served from 2008 to 2018. He established and directed the national infrastructure for academic chemical biology and drug screening (Nor-Openscreen, coupled with EU-Openscreen) and served as the national director for EATRIS (translational medicine). Taskén has been key in building the national cancer precision medicine initiative for Norway (InPreD molecular diagnostics infrastructure, IMPRESS-Norway national clinical trial and CONNECT public-private partnership), is Director of the OUH Centre for Precision Cancer Medicine and is involved in developing precision medicine on a European arena as the Cancer Mission PRIME-ROSE project for DRUP-like clinical trials across Europe and will lead the Work Package on treatment in the Joint Action for Precision Cancer Medicine to start Nov 2025.

Taskén received the Anders Jahre Medical Prize for Young Scientists in 2002, won the King Olav V's Prize for Cancer Research in 2016, the University of Oslo Innovation Prize in 2023, and received the OUH Excellent Researcher Award in 2024. He was elected to the Norwegian Academy of Science and Letters in 2005 and currently serves as Vice-President and Head of the Academy's Natural Sciences Class. Taskén is the author of more than 300 publications and an inventor of over 20 patents (more than 18,000 citations, h-index = 71). Current research is in tumor immune evasion mechanisms and functional precision medicine for different solid and blood cancers.

Selected recent publications:

1. García-Díaz N, Wei Q, Taskén K. Small molecule inhibitors targeting regulatory T cells for cancer treatment. *Eur J Immunol.* 2023; 54(2): e2350448.
2. Hermansen JU, Yin Y, Urban A, Myklebust CV, Karlsen L, Melvold K, Tveita AA, Taskén K, Munthe LA, Tjønnfjord GE, Skånland SS. A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine. *Cell Death Discov.* 2023; 9(1): 125.
3. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES et al. A national precision cancer medicine implementation initiative for Norway. *Nat Med.* 2022; 28(5): 885.
4. Flobak Å, Skånland SS, Hovig E, Taskén K, Russnes HG. Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. *Trends Pharmacol Sci.* 2022; 43(11): 973–86.

As part of the Brno Oncology Days, Prof. Kjetil Taskén will present an invited lecture on „Advancing Precision Cancer Medicine by Building National Initiatives and via European Collaboration“.



Prof. Christos Toumpanakis, MD, PhD, FRCP, FEBGH, AGAF

Centre for Gastroenterology & Neuroendocrine Tumour Unit – ENETS Centre of Excellence of Royal Free Hospital, London, UK

MANAGEMENT OF CARCINOID SYNDROME – IMPLEMENTATION OF GUIDELINES INTO CLINICAL PRACTICE

Friday 5. 9. 2025, 12:05 p.m., R. Werner Hall

Professor Christos Toumpanakis is a Consultant in Gastroenterology & Neuroendocrine Tumours (NET) at Centre for Gastroenterology & Neuroendocrine Tumour Unit – ENETS Centre of Excellence of Royal Free Hospital in London since 2008.

He graduated from Medical School-University of Athens in 1994, obtained his Specialty Title in Gastroenterology & Hepatology in 2004, following 2 years of training in Internal Medicine and 4 years Gastroenterology & Hepatology in one of the largest Teaching Hospitals in Athens. He received a scholarship from Greek Society of Gastroenterology for „Neuroendocrine Tumours“ in 2004. In 2007, he obtained his PhD from University of Athens, Medical School. In 2008, he was appointed as a „Consultant“ at Royal Free Hospital, London. He has been awarded 7 times, by the 4th Year University College of London (UCL) Medical Students, as „Top-Teacher of the Year“. In October 2022, he was promoted to a „Professor of Gastroenterology & Neuroendocrine Tumours“ at the Medical School of UCL.

He is the deputy lead of Royal Free NET Unit and has substantial experience in all types of NETs and in all available treatment options. Royal Free Hospital London NET Unit is the largest NET Unit in UK and one of the largest NET Units globally, with an active cohort of more than 3,000 NET patients.

He was the Chair of the Advisory Board of the European Neuroendocrine Tumour Society (ENETS) between 2020–2022, steering international and inter-disciplinary research and education projects, co-Chair of the Post-Graduate Course of ENETS annual Conference, co-Editor of ENETS CME program, co-Author of UK and Ireland NET Society (UKINETS) & European NET Society Guidelines. For 4 years, he was the Chair of the Program Organizing

Committee of UKINETS Conference and a member of UKINETS Executive Committee. He is the Senior Author of the new ENETS 2022 Guidelines for „Carcinoid Syndrome and Carcinoid Heart Disease“. He is a member of the Senior Editorial Board of Journal of Neuroendocrinology. He is lecturing on a regular basis in several National & International Conferences and published more than 150 original papers and reviews in peer reviewed journals with H-Index: 33.

Selected recent papers:

1. Papaefthymiou A, Laskaratos FM, Koffas A, Manolakis A, Gkolfakis P, Coda S, Sodergren MH, Toumpanakis C. State of the art in endoscopic therapy for the management of gastroenteropancreatic neuroendocrine tumors. *Curr Treat Options Oncol*. 2022; 23(7): 865–880.
2. Nesti C, Laskaratos FM, Mandair D, Caplin ME, Toumpanakis C. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: A retrospective, multicentre, international cohort study. *Lancet Oncol*. 2023; 24(2): 161–170.
3. Gertner A, Tsoi M, Hayes AR, Furtado O'Mahony R, Laskaratos FM, Glover AR, Karia N, Butt M, Eastwood J, Mandair D, Caplin ME, Toumpanakis C. The clinical utility of the NETest in patients with small intestinal neuroendocrine neoplasms (Si NENs): A real life study. *Cancers (Basel)*. 2024; 16(13): 3103.
4. Kalligeros M, Diamantopoulos L, Toumpanakis C. Biomarkers in small intestine NETs and carcinoid heart disease: A comprehensive review. *Biology (Basel)*. 2021; 10(9): 846.

As part of the Brno Oncology Days, Prof. Christos Toumpanakis will present an invited lecture on „Management of Carcinoid Syndrome – Implementation of Guidelines into Clinical Practice“.

Diagnostic and treatment centres in MMCI

The MMCI has **22 diagnostic and treatment centres**, which focus on different cancer types, treatment procedures or supportive care services.

Treatment centres deliver comprehensive cancer care based on interdisciplinary teamwork of specialist physicians and other non-medical healthcare professionals.

The concept of treatment centres enables us to provide **high-quality medical services** to MMCI patients and to share our expertise with other healthcare institutions within the region. Furthermore, MMCI provides **access to the most innovative diagnostics** and cancer treatment options **including robotic surgery, theranostics, precision oncology and radiotherapy**.



Breast Cancer Centre

Centres for Gastrointestinal tumors

- Centre for Oesophageal and Gastric Cancer
- Colon Cancer Centre
- Centre for Liver and Biliary Tract Cancer
- Centre for Pancreatic Cancer

Centres for Urologic tumors

- Prostate Cancer Centre
- Kidney and Urinary Tract Cancer Centre
- Testicular Cancer Centre

Centres for Gynecologic tumors

- Centre for Ovarian, Tubal and Peritoneal Cancers
- Centre for Uterine, Cervical and Vulvar Cancers

Centre for Lung and Pleural Cancer

Centre for Skin Cancer and Melanoma

Centre for Brain and Spinal Cord Tumours

Head and Neck Cancer Centre

Sarcoma centre

Centre for Neuroendocrine Tumours

Thyroid Cancer Centre

Centre for cancer of unknown primary and other rare malignancies

Centre for Precision Oncology

Robotic Surgery Centre

Centre for Palliative Medicine and Pain Management

Centre for cytoreduction and regional chemotherapy

Masaryk Memorial Cancer Institute



Masaryk Memorial Cancer Institute (MMCI) is **the largest cancer centre in the Czech Republic** in terms of the number of primarily treated adult patients with solid tumors and the provision of preventive cancer care. **Almost 5 000 newly diagnosed cancer patients** start treatment in MMCI every year. MMCI currently plays the role of the National cancer centre in the network of Czech Comprehensive Cancer Centres.

MMCI is an internationally recognized Institute, an accredited member of **the Organisation of European Cancer Institutes (OECI)** and **ESMO Designated Centre of Integrated Oncology and Palliative Care**. MMCI is also a member of ERN network for rare adult solid cancers EURACAN and for genetic tumor risk syndromes GENTURIS.

MMCI serves as a national node of the **BBMRI-ERIC** research infrastructure for biobanking and is a partner of Czech Clinical Research Infrastructure Network (CZECRIN).

1 175 employees, of whom 136 hold a scientific degree
220 inpatient beds / 8 540 inpatient cases
44 beds in 2 day care units / 32 078 treatment applications
52 number of outpatient clinics / 560 879 outpatient treatments
5 605 operations, including robotic surgeries
650 923 radiotherapy procedures
192 peer-reviewed publications
138 clinical trials
A+ rating from patients

MMCI is providing **health care services, research and education** in the areas of prevention, diagnosis and treatment of solid tumors. MMCI is affiliated to Masaryk University, within which it cooperates with two other university hospitals: University Hospital Brno and St. Anne's University Hospital. MMCI operates its own facility for basic and translational research called **RECAMO** (Research Centre for Applied Molecular Oncology) and provides full support for **clinical research, including Phase I Clinical Trial Unit**, biobanking and precision oncology programme.

